O07 Randomised, open labelled clinical trial to investigate synovial mechanisms determining response: resistance to rituximab versus tocilizumab in RA patients failing TNF inhibitor therapy
Frances Humby(Queen Mary University of London), Costantino Pitzalis(Queen Mary University of London), Bernard Lauwerys(UCB Pharma (Belgium)), Juan D. Cañete(Hospital Clínic de Barcelona), Arthur G. Pratt, Vasco C. Romão(Unknown), Carlomaurizio Montecucco(University of Pavia), Rebecca Hands, Giovanni Giorli(Queen Mary University of London), Peter Sasieni(Queen Mary University of London), Mattia Bellan(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Pier Paolo Sainaghi(Università degli Studi del Piemonte Orientale “Amedeo Avogadro”), Hasan Rizvi(Queen Mary University of London), Alberto Cauli(University of Cagliari), Liliane Fossati(University of Geneva), Felice Rivellese(Queen Mary University of London), Maya H Buch(Arthritis UK), João Eurico Fonseca(University of Lisbon), John D. Isaacs(Newcastle upon Tyne Hospitals NHS Foundation Trust), Georgina Thornborn(Queen Mary University of London), Myles Lewis(Queen Mary University of London), Christopher Holyroyd(University of Southampton), Nagui Gendi(Basildon Hospital), Pauline Ho(Manchester Royal Infirmary), Bhaskar Dasgupta(Anglia Ruskin University), Serena Bugatti, Mattia Congia, Robert J. Moots(Edge Hill University), Ernest Choy(Cardiff University), Christopher J Edwards(University Hospital Southampton NHS Foundation Trust), Patrick Durez(Cliniques Universitaires Saint-Luc), Patrick Verschueren(Universitair Ziekenhuis Leuven), Peter C. Taylor(Nuffield Orthopaedic Centre), Stephen Kelly(Barts Health NHS Trust), Charlie S. Thompson(University of Ottawa), Piero Reynolds(Homerton University Hospital), Arti Mahto(King's College Hospital NHS Foundation Trust), Chris John(Queen Mary University of London), Nora Ng(Queen Mary University of London), Alessandra Nerviani(Queen Mary University of London)
Cited by 2
Related Papers
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update
|Annals of the Rheumatic Diseases|2020|2.8k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
2022 update
|Radboud Repository (Radboud University)|2010|1.6k
A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy
|New England Journal of Medicine|2019|1.5k